Fig. 1From: Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patientsCumulative probabilities of virological failure (Panel a) and of treatment failure (Panel b) after switch to a rilpivirine- and or to an integrase inhibitor (InSTI)-based regimen. RPV: rilpivirine; InSTI: integrase strand transfer inhibitor; FTC: emtricitabine; TDF: ftenofovir disoproxil fumarateBack to article page